Unique Advantages of AM06
Safer strain from human milk breast
AM06 is the only strain on the market isolated from the breast milk of healthy women.
Patented strain
Scientific data support
Eight in vivo and in vitro functional validation studies, two comprehensive toxicology and safety studies, and two published research papers.
Shelf stable
The raw material has a shelf life of 36 months, can be stored at room temperature without refrigeration.
cGMP standard
The first live biotherapeutic research technology system and production platform in China, manufactured according to U.S. cGMP standards.
High quality standard
Proprietary Heat-InActived® Technology: Preserves high-quality active components through precise heat inactivation. Complies with U.S. FDA postbiotic-grade quality control standards.
Third-party tested
Third-Party Quality Assurance: Certified by SGS for quality assurance, ensuring reliable and high standards.
AM06 Safety
AM06™ has been extensively tested for safety, showing no virulence or resistance genes, confirming its high safety and suitability for use based on comprehensive genome sequencing and EFSA guidelines.
AM06 has undergone comprehensive toxicological and safety studies, with its inactivation process eliminating the risk of live bacterial infection, thus enhancing its applicability and safety profile. Full genome sequencing of AM06 meets the 2021 EFSA guidelines for whole-genome analysis, including preliminary assessments of virulence genes, resistance genes, and mobile genetic elements. The results confirm that AM06 contains no virulence or resistance genes, affirming its safety for use.
Main Research Areas and Outcomes
AM06™ has been extensively studied, showing benefits in improving insulin sensitivity, reducing fat accumulation in NAFLD, enhancing glucose control in diabetes, supporting anticancer immunity, and strengthening gut health.
Metabolic Diseases
AM06™ has been shown to significantly improve insulin sensitivity and reduce fat accumulation, making it a beneficial aid in the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD), and it also enhances glucose control, proving effective in managing Diabetes.
Tumor Suppression
Cancer Treatment: In certain cancer models, AM06™ has demonstrated anticancer potential by modulating immune responses and enhancing antitumor immunity.
Gastrointestinal Health
AM06™ enhances intestinal barrier function, reduces pathogen invasion, and improves gut health.
AM06 Function
All applications and therapeutic effects of AM06™ are backed by rigorous scientific validation and research.
AM06™ Akkermansia Muciniphila shows great potential in the prevention and treatment of various diseases through its multifaceted mechanisms of action.
Patents
18 Patents
18 patent applications have been filed for AM06™, with six already granted.
Articles
Articles
Related research findings have been published in multiple journals.
Articles list
- Hou, Fengyi et al. “Safety Evaluation and Probiotic Potency Screening of Akkermansia muciniphila Strains Isolated from Human Feces and Breast Milk.” Microbiology spectrum, vol. 11,2 e0336122. 14 Feb. 2023, doi:10.1128/spectrum.03361-22
- Li, Tao et al. “Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells.” Frontiers in immunology vol. 13 1047570. 1 Dec. 2022, doi:10.3389/fimmu.2022.104757
- Su Peizhu et al.“Isolation and identification of a strain of Akkermansia muciniphila from healthy human colostrum”，Journal of microbiology vol. doi:10.3969/j.issn.1005-7021.2024.05.009
